Researchers knock EMA over trial reporting and access to 'commercial' raw data
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is again under fire for the way it makes public clinical trial-related information. Researchers writing in the British Medical Journal have criticised how the agency reports Phase III trial results in its European public assessment reports (EPARs). The criticism comes less than a week after the agency defended itself against another British Medical Journal article accusing regulators of putting drug company profits ahead of patient wellbeing when it comes to allowing access to unpublished trial reports.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.